Like any clinical trial, ASPIRE faces certain limitations and challenges. One major challenge is the heterogeneity of cancer, which means that not all patients respond equally to the same treatment. Moreover, the complexity of managing combination therapies, with potential increased toxicity, requires careful monitoring and dose adjustments. Additionally, long-term follow-up is essential to fully understand the durability of the treatment benefits and any late-onset side effects.
